Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia 9Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 6Primary Immunodeficiency Diseases 3Multiple Myeloma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoproliferative Disorders 3Immune System Diseases 3Hodgkin Disease 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemoglobinopathies 2Fanconi Anemia 2Cytokine Release Syndrome 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Recurrence 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 17Rituximab 11fludarabine 9Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Busulfan 7fludarabine phosphate 6Tacrolimus 6Melphalan 6Whole-Body Irradiation 5Doxorubicin 5Vincristine 4Prednisone 4Mesna 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4ibrutinib 3Thiotepa 3Sirolimus 3Cyclosporine 3Bortezomib 3ponatinib 2Vorinostat 2Stem Cell Transplantation 2Rifampin 2Platelet Transfusion 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × AP 1903 reagent × Lymphoid × Clear all
NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡